Allist Pharmaceuticals

AUG 14, 2026 · PHASE 1 TRIAL

Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation

ClinicalTrials.gov

Phase 1b registry record with recruitment completed but no results posted; describes planned efficacy and safety exploration in a small, dose-ranging study of a novel agent.

AUG 13, 2026 · PHASE 1/2 TRIAL

A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1

ClinicalTrials.gov

This is a Phase 1/2 trial registration with no results posted; it describes planned enrollment and primary outcome measures but reports no clinical data, efficacy, or safety findings.

AUG 13, 2026 · PHASE 3 TRIAL

Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation

ClinicalTrials.gov

This is a Phase 3 RCT registration with no posted results; the study is actively recruiting and outcomes are not yet reported.

AUG 13, 2026 · PHASE 1/2 TRIAL

A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China

ClinicalTrials.gov

Phase 1/2 trial in early stage of recruitment with no results yet posted; primary outcomes are safety and dose-finding rather than efficacy.